A DGIST research team, led by Professor Kyung-In Jang, has developed a smart patch capable of real-time biometric signal ...
Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...
Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...
Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time, ...
RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...
In the Spring 2024 semester, Glucoguard was invited to participate in the MADO program through our ongoing relationship with ...
The study met its primary endpoint with no procedure or device related serious adverse events reportedRUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GCTK) (“Glucotrack” or the “Company” ...
The remote patient monitoring (RPM) technology that a patient uses while receiving hospital-at-home care does not follow a ...
New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms can overlap between diabetes and dementia.
Remember when tracking your steps felt revolutionary? Well, CGMs are taking health monitoring to a whole new level.
Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ...